Moderna Begins Testing First Vaccine for Deadly Ebola Strain
Ottawa, Tuesday, 4 August 2026.
Moderna has launched human trials for a new vaccine targeting the Bundibugyo Ebola virus, addressing a growing outbreak in Africa for which no approved protection currently exists.
Clinical Trial Initiation and Corporate Strategy
On 4 August 2026, Moderna, Inc. (NASDAQ: MRNA) announced the vaccination of the first participants in a Phase 1 clinical trial for mRNA-1469, an investigational vaccine against the Bundibugyo ebolavirus [1]. The study, identified as NCT07737717, is being conducted across three sites in Canada to evaluate safety, tolerability, and immunogenicity in healthy adult participants [1][2]. This move underscores Moderna’s strategy to leverage its proprietary mRNA technology against global health threats where no licensed vaccines currently exist [1]. The Phase 1 study aims to enroll approximately 80 healthy adults to assess the vaccine candidate’s profile [1].
Epidemiological Urgency and Public Health Designations
The Bundibugyo strain is currently driving an active outbreak in the Democratic Republic of the Congo, resulting in over 3,000 confirmed cases and more than 1,400 deaths [1]. Due to the severity of the situation, the World Health Organization has declared the outbreak a Public Health Emergency of International Concern, while the Africa CDC has issued a Public Health Emergency of Continental Security [1]. Unlike the Zaire ebolavirus, there are no currently approved vaccines indicated for this specific strain, heightening the urgency for effective countermeasures [1]. Cases are rising more quickly than they did in the 2014 - 2016 West Africa epidemic which remains the largest on record [1].
Funding Commitments and Trial Logistics
The Coalition for Epidemic Preparedness Innovations (CEPI) is partnering with Moderna on this initiative, committing up to US $50 million to support preclinical testing and the manufacture of additional doses [1]. Under the agreement, Moderna commits to providing at least 500,000 doses to low- and middle-income countries at access pricing if the vaccine is licensed [1]. The trial locations are confirmed in Halifax and Truro, Nova Scotia, as well as Toronto, Ontario, utilizing facilities such as the Canadian Center for Vaccinology [2]. Enrollment for the trial is ongoing with no specific completion date provided in the initial announcement [1].